Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
HCC1806	MK2206	3	72	sigmoid	sigmoid	HCC1806 MK-2206 0 3 72	8	3.199	74.1	0.843	0.0434	320.0	-0.491	0.468	0.981	6.96e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.46e-05	NA
HCC1806	PI103	1	72	sigmoid	sigmoid	HCC1806 PI-103 0 1 72	8	2.673	Inf	0.895	0.00682	1.71	0.853	1.43	0.781	0.0106	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	2	72	sigmoid	sigmoid	HCC1806 PI-103 0 2 72	8	2.758	Inf	0.898	0.00662	1.71	0.857	1.43	0.781	0.0105	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	PI103	3	72	sigmoid	sigmoid	HCC1806 PI-103 0 3 72	8	3.126	Inf	0.91	0.00588	1.72	0.873	1.43	0.782	0.0103	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	Trametinib	1	72	sigmoid	sigmoid	HCC1806 trametinib 0 1 72	8	2.751	Inf	0.795	0.139	0.00972	0.802	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	2	72	sigmoid	sigmoid	HCC1806 trametinib 0 2 72	8	2.836	Inf	0.8	0.135	0.00973	0.808	0.873	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	Trametinib	3	72	sigmoid	sigmoid	HCC1806 trametinib 0 3 72	8	3.204	Inf	0.822	0.12	0.00981	0.829	0.872	0.97	2.67e-05	NA	Inf	0.742	0.822	0.00864	0.752	0.892	0.97	2.67e-05	NA
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.0	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.0	0.634	0.01	0.541	0.0969	0.833
Hs 578T	Alpelisib	3		sigmoid	sigmoid	Hs578T alpelisib 3	8	2.856	Inf	0.712	0.0759	0.872	0.616	0.828	0.963	5.21e-05	NA	Inf	0.641	0.901	0.65	0.553	0.853	0.955	8.85e-05	NA
Hs 578T	CAL-101	2		sigmoid	sigmoid	Hs578T idelalisib 2	8	2.534	57.5	0.801	0.0636	320.0	-0.507	0.408	0.979	9.58e-06	NA	Inf	0.766	0.923	4.27	0.505	0.495	0.975	1.65e-05	NA
Hs 578T	CAL-101	3		sigmoid	sigmoid	Hs578T idelalisib 3	8	2.874	Inf	0.854	0.0202	1.12	0.835	1.91	0.991	6.68e-07	NA	Inf	0.805	0.972	1.07	0.781	1.92	0.99	9.77e-07	NA
Hs 578T	Everolimus	3		flat	flat	Hs578T everolimus 3	8	2.848	Inf	0.664	0.299	0.0	0.664	0.01	0.475	0.144	0.702	Inf	0.592	0.631	0.0	0.592	0.01	0.486	0.136	0.632
Hs 578T	KIN001-244	1		sigmoid	sigmoid	Hs578T KIN001-244 1	8	2.041	24.7	0.739	0.0391	4.05	0.414	0.972	0.968	3.4e-05	NA	Inf	0.752	0.962	3.15	0.51	0.99	0.964	4.65e-05	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
Hs 578T	MK2206	2		sigmoid	sigmoid	Hs578T MK-2206 2	8	2.530	Inf	0.664	0.131	0.0699	0.752	1.34	0.75	0.0156	NA	Inf	0.628	0.848	0.0616	0.717	1.21	0.767	0.0126	NA

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)